|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Involvement of aurora kinase B (AURKB) and Wee1-like protein kinase (WEE1) as downstream proteins in the (V600E)B-RAF pathway was validated in xenografted tumors, and mechanisms of action were characterized in size- and time-matched tumors.
|
23416158 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone H3 phosphorylation precedes the induction of apoptosis in p53-/- tumour cell lines but does not appear to be required for this fate as an Aurora kinase inhibitor suppresses phosphorylation of both Aurora B and histone H3 but has little effect on cell death.
|
24853431 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, dual therapy with trastuzumab and lapatinib resulted in significant antitumor activity only in ARK2 and EnCa1 tumors.
|
25294905 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with peripheral T-cell lymphoma, not otherwise specified and normal γδ T cells, HSTL overexpressed genes encoding NK-cell-associated molecules, oncogenes (FOS and VAV3), the sphingosine-1-phosphatase receptor 5 involved in cell trafficking, and the tyrosine kinase SYK, whereas the tumor-suppressor gene AIM1 (absent in melanoma 1) was among the most down-expressed.
|
22510872 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, aurora B was positively related to grading and tumor size and negatively to differentiation and functionality.
|
29970506 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated the effects of the bona fide Aurora-B kinase inhibitor AZD1152 on tumor responses to ionizing radiation (IR).
|
18084327 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Informative TMA results were obtained in 91 tumor cases for Aurora-B and 93 tumor cases for FOXM1.
|
25986250 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knocking down of Aurora B with shRNA substantially inhibited HCC cell proliferation, colony formation and delayed tumor growth in nude mice.
|
30263005 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytosolic staining intensity of the ARK2 protein was associated with tumor stage (p = 0.006) and tumor size (T) of TNM staging system (p = 0.026).
|
23504335 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we found that the tumor suppressive effect of Aurora-B and HDAC inhibition is due to the induction of cell cycle arrest and/or apoptosis.
|
26638998 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromosome instability in tumor cells due to defects in Aurora B mediated error correction at kinetochores.
|
30513041 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth was significantly lower in AKB-LfNPs alone and in combination with TMZ treated mice and increased the survival by 2.5-times.
|
30334671 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GSK1070916 is a potent, selective, ATP competitive inhibitor of Aurora kinase B and C. Translation of predictive biomarkers to the clinic can benefit patients by identifying the tumors that are more likely to respond to therapies, especially novel inhibitors such as GSK1070916.
|
21762492 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation.
|
21646403 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aurora B kinase and survivin, major components of the CPC, were particularly upregulated in high-grade carcinomas and may therefore comprise therapeutic targets for these tumors.
|
23929435 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of experiment indicated that specific knockdown of Aurora kinase B led to prostate carcinoma cells apoptosis and inhibited tumor growth.
|
28100163 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intravenous VVNIS-C was more effective at controlling AN3 CA xenograft growth than VVNIS-W, while both VVNIS-C and VVNIS-W ceased tumor growth and induced tumor regression in 100% of mice bearing ARK-2 xenografts.
|
24434058 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In comparative <i>in vivo</i> experiments, GS-5829 and/or GS-626510 were found more effective than JQ1 at the concentrations/doses used in decreasing tumor growth in both USC-ARK1 and USC-ARK2 mouse xenograft models.<b>Conclusions:</b> GS-5829 and GS-626510 may represent novel, highly effective therapeutics agents against recurrent/chemotherapy-resistant USC-overexpressing c-Myc.
|
29941483 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We did a CRISPR/Cas9-based screen that showed that <i>RB1</i><sup>-/-</sup> SCLC are hyperdependent on <i>AURKB</i>, likely because both genes control mitotic fidelity, and confirmed that Aurora B kinase inhibitors are efficacious against <i>RB1</i><sup>-/-</sup> SCLC tumors in mice at nontoxic doses.<i>See related commentary by Dick and Li, p. 169</i>.<i>This article is highlighted in the In This Issue feature, p. 151</i>.
|
30373918 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
LINE-1 hypomethylation and AIM1 hypermethylation have prognostic utility in both melanoma patients' tumors and serum.
|
22402438 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
aurora B kinase is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug to treat tumors.
|
27704720 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, AURKB-Sv2 variant form is associated with a higher level of serum alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II (PIVKAII), tumor capsular invasion, multiple tumor formation and at an age younger than those with other variant forms (P < 0.05).
|
19134008 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed Aurora B expression in gcGB (n = 28) and GB (n = 54) patient tumor samples by immunohistochemistry; 17 gcGB and 22 GB samples were analyzed at the DNA and mRNA levels.
|
20467329 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neither baseline tumor expression of AURKA (ROC = 0.57, P = 0.46) nor AURKB (ROC = 0.56, P = 0.87) predicted for ypT2-4 status.
|
31597600 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Univariate, multivariate and Kaplan-Mayer analyses documented the lack of association between Aurora-A or Aurora-B expression and clinicopathological parameters such as gender, age, tumor size, histology, TNM stage, lymph node metastasis and BRAF status as well as disease recurrences or disease-free interval.
|
25807528 |
2015 |